Eli Lilly & Co. vs. PTC Therapeutics, Inc.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| LLY | PTCT | |
|---|---|---|
| Market Cap | $1.05 trillion | $5.98 billion |
| Revenue (TTM) | $79.67 billion | $1.01 billion |
| Net Income (TTM) | $26.71 billion | $-38,382,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | PTCT | |
|---|---|---|
| P/E Ratio | 39.62 | — |
| Price / Book | 31.05 | -36.19 |
| Price / Sales | 13.20 | 5.93 |
PTCT leads on 2 of 2 valuation factors.
Profitability
| LLY | PTCT | |
|---|---|---|
| Net Margin | 33.53% | -3.80% |
| Return on Equity | 78.84% | 23.21% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | PTCT | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 23.23 | — |
LLY and PTCT split the dividend factors evenly.
Risk & Sentiment
| LLY | PTCT | |
|---|---|---|
| Short Interest | 1.29% | 7.88% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, PTCT overview, PTCT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.